XyloCor finds new backing to push regenerative heart disease gene therapy deeper into the clinic
XyloCor Therapeutics is one step closer to accomplishing the tough task of delivering gene therapies straight into the heart for coronary artery disease.
Three years after its first fundraise, XyloCor has raised an additional $22.6 million in a Series A extension, with the goal of expanding its lead program into further trials. Called XC001, the program is currently being studied in patients who have refractory angina, and XyloCor wants to study its use as a potential adjunctive for those undergoing bypass surgery.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,500+ biopharma pros reading Endpoints daily — and it's free.